Vicore Pharma Holding (NASDAQ:VCRE) Stock Short Interest Report for September

Vicore Pharma Holding (NASDAQ:VCRE) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 4,238 shares, a decrease of 57.0% from the September 15th total of 9,857 shares. Based on an average daily volume of 39,075 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

A number of equities research analysts have commented on VCRE shares. Weiss Ratings started coverage on Vicore Pharma in a research report on Thursday. They issued a “sell (e-)” rating on the stock. Jefferies Financial Group began coverage on Vicore Pharma in a report on Friday. They set a “buy” rating and a $25.00 price target for the company. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Vicore Pharma currently has an average rating of “Hold” and an average target price of $25.00.

Vicore Pharma Stock Performance

Shares of VCRE traded down $0.25 during midday trading on Tuesday, hitting $8.98. 23,257 shares of the stock were exchanged, compared to its average volume of 27,891. Vicore Pharma has a 52-week low of $7.88 and a 52-week high of $17.80.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.